Accolade (NASDAQ:ACCD) Shares Gap Down After Analyst Downgrade

Accolade, Inc. (NASDAQ:ACCD) shares gapped down prior to trading on Friday after Morgan Stanley lowered their price target on the stock from $13.00 to $12.00. The stock had previously closed at $9.19, but opened at $7.87. Morgan Stanley currently has an equal weight rating on the stock. Accolade shares last traded at $8.19, with a volume of 200,076 shares trading hands.

A number of other equities research analysts also recently weighed in on the stock. Needham & Company LLC lowered their target price on shares of Accolade from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday. Canaccord Genuity Group lowered their target price on shares of Accolade from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Truist Financial lowered their target price on shares of Accolade from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday. Wells Fargo & Company raised their target price on shares of Accolade from $10.00 to $12.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 9th. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Accolade in a research note on Monday, February 26th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ACCD. BluePath Capital Management LLC bought a new position in shares of Accolade in the third quarter worth approximately $28,000. DekaBank Deutsche Girozentrale bought a new position in shares of Accolade in the third quarter worth approximately $28,000. AJOVista LLC bought a new position in shares of Accolade in the fourth quarter worth approximately $68,000. Allspring Global Investments Holdings LLC bought a new position in shares of Accolade in the first quarter worth approximately $87,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Accolade by 84.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,928 shares of the company’s stock worth $126,000 after purchasing an additional 5,455 shares during the last quarter. Institutional investors own 84.99% of the company’s stock.

Accolade Price Performance

The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 0.48. The stock has a market cap of $610.76 million, a P/E ratio of -5.93 and a beta of 2.08. The firm’s fifty day moving average price is $9.66 and its 200-day moving average price is $9.92.

Accolade (NASDAQ:ACCD) last issued its earnings results on Thursday, April 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.57%. The firm had revenue of $124.80 million for the quarter, compared to analysts’ expectations of $123.91 million. During the same quarter last year, the business earned ($0.42) earnings per share. The business’s revenue was up 26.1% on a year-over-year basis. Analysts forecast that Accolade, Inc. will post -1.2 earnings per share for the current year.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.